+Search query
-Structure paper
| Title | Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. |
|---|---|
| Journal, issue, pages | Sci Transl Med, Vol. 17, Issue 809, Page eady6831, Year 2025 |
| Publish date | Jul 30, 2025 |
Authors | K Rachael Parks / Zoe Moodie / Mary A Allen / Catherine Yen / Briana D Furch / Kellie J MacPhee / Gabriel Ozorowski / Jack Heptinstall / William O Hahn / Zihan Zheng / Huiyin Lu / Shannon Grant / Elize Domin / Michael O Duff / Aaron Seese / Constanza Marini-Macouzet / Lamar Ballweber-Fleming / Wen-Hsin Lee / Christopher A Cottrell / Alessia Liguori / Erik Georgeson / Nushin Alavi / Michael Kubitz / Nicole Phelps / Kelly E Seaton / Kristen W Cohen / Maija A Anderson / Kajari Mondal / Dagna S Laufer / James G Kublin / Andrew B Ward / Ollivier Hyrien / Stephen C De Rosa / Sunny Himansu / Brett Leav / Caroline Reuter / Georgia D Tomaras / David Montefiori / Stephen R Walsh / Ian Frank / Magdalena E Sobieszczyk / Paul A Goepfert / Kathryn E Stephenson / Lindsey R Baden / Hong Van Tieu / Michael C Keefer / Jesse Clark / Sharon A Riddler / William R Schief / M Juliana McElrath / ![]() |
| PubMed Abstract | mRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope ...mRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope trimers, including two doses of soluble and membrane-anchored forms, in a randomized, open-label, phase 1 clinical trial. Vaccines were generally well tolerated, although 6.5% (7 of 108) of participants developed urticaria, a higher proportion than seen with other mRNA vaccines. mRNA-encoded trimers induced strong envelope-specific B and T cell responses. Immunization with membrane-anchored trimers, intended to obscure epitopes at the trimer base targeted by nonneutralizing antibodies, reduced the frequency of base-binding serum antibodies in comparison with soluble trimers. Three immunizations elicited autologous tier 2 serum neutralizing antibodies in 80% of vaccinees receiving the membrane-anchored trimers, in contrast to only 4% receiving the soluble trimer. Thus, with demonstration of more favorable safety, mRNA-encoded membrane-anchored HIV envelope trimers represent a promising platform for HIV vaccine clinical development. |
External links | Sci Transl Med / PubMed:40737434 / PubMed Central |
| Methods | EM (single particle) |
| Resolution | 26.0 - 30.0 Å |
| Structure data | ![]() EMDB-70340: FH_302_07 Fab in complex with BG505 MD39.3 SOSIP (negative stain) ![]() EMDB-70341: FH_302_14 Fab in complex with BG505 MD39.3 SOSIP (negative stain) ![]() EMDB-70342: FH_302_23 Fab in complex with BG505 MD39.3 SOSIP (negative stain) ![]() EMDB-70343: BG505 MD39.3-CC5 SOSIP in complex with V1V3 epitope polyclonal Fabs isolated from HVTN302 human trial after dose 3 of mRNA-gp151-CD4KO immunization ![]() EMDB-70344: BG505 MD39.3-CC5 SOSIP in complex with gp41-base epitope polyclonal Fabs isolated from HVTN302 human trial after dose 3 of mRNA-gp151-CD4KO immunization ![]() EMDB-70345: BG505 MD39.3-CC5 SOSIP in complex with C3V5 epitope polyclonal Fabs isolated from HVTN302 human trial after dose 3 of mRNA-gp151-CD4KO immunization |
| Source |
|
Movie
Controller
Structure viewers
About Yorodumi Papers



Authors
External links






Human immunodeficiency virus 1